Generating LTi-like NK-22 Cells from CD34+ Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining NK cells are limited, as they can only be derived from peripheral blood, while LTi-like NK-22 cells, which are crucial for certain clinical applications, can only be obtained from invasive procedures in secondary lymphoid tissues, making them difficult to study and utilize effectively.
Innovation Solution
A novel method to generate NK cells and LTi-like NK-22 cells from hematopoietic stem cells (HSCs) by culturing CD34+ cells with specific cytokines such as IL-3, stem cell factor, FLT-3L, IL-7, and IL-15, and using stroma and hydrocortisone, allowing for the expansion and differentiation of these cells without the need for invasive tissue sampling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If NK cells are derived from peripheral blood, then they can be obtained through non-invasive procedures, but LTi-like NK-22 cells cannot be obtained as they are restricted to secondary lymphoid tissues
Solution Approach 1:
The invention segments the acquisition process into two parts: (1) obtain hematopoietic stem cells from easily accessible sources like peripheral blood or cord blood, and (2) differentiate these stem cells in vitro into the desired NK or LTi-like NK-22 cell types using specific cytokine combinations. This resolves the contradiction by making both cell types accessible through non-invasive initial sampling while maintaining the ability to generate restricted cell types through controlled differentiation.
Solution Approach 2:
The invention uses hematopoietic stem cells as an intermediary population that can be obtained non-invasively from peripheral blood. These stem cells serve as a common precursor that can be differentiated into multiple cell types including both standard NK cells and the previously inaccessible LTi-like NK-22 cells, using specific cytokine mediators like IL-3, SCF, FLT-3L, IL-7, and IL-15.
2Reliability
If LTi-like NK-22 cells are obtained from secondary lymphoid tissues, then authentic cell types are obtained, but invasive procedures are required
Solution Approach 1:
The invention performs preliminary differentiation of hematopoietic stem cells into LTi-like NK-22 cells under controlled in vitro conditions before they would naturally require invasive tissue sampling. By pre-differentiating the cells using specific cytokine protocols, the method produces authentic LTi-like NK-22 cells with the expected phenotype (CD56dimCD117+CD94-) and function (IL-22 production) without requiring subsequent invasive procedures.
Solution Approach 2:
The invention creates an in vitro copy of the LTi-like NK-22 cell population that naturally exists in secondary lymphoid tissues. By using hematopoietic stem cells as a model system and applying specific differentiation protocols, the method reproduces the authentic cell type's characteristics, phenotype, and function in a controllable laboratory setting, eliminating the need for invasive tissue sampling.
3Measurement precision
If small quantities of material from aborted fetal tissue or surgical specimens are used, then LTi-like NK-22 cells can be studied, but the quantity of material is limited and pathology may be present
Solution Approach 1:
The invention changes the source parameter from restricted tissue samples to expandable hematopoietic stem cells. Starting with a small number of CD34+ stem cells, the method uses cytokine-driven proliferation and differentiation to generate large quantities of LTi-like NK-22 cells (millions of cells from thousands of stem cells), thereby solving the material quantity limitation while maintaining cellular authenticity and avoiding pathological samples.
Data Source
AI summary
The present invention relates generally to methods to prepare NK and LTi-like, NK22 cells from HSCs and uses of those cells.